Chandra Bhagat Pharma Limited

Chandra Bhagat Pharma Limited, established in 1944, is a Mumbai-based pharmaceutical company specializing in the marketing of critical care and healthcare products both domestically and internationally. The company offers a diverse range of pharmaceutical formulations, including intravenous and intramuscular injections, tablets, and capsules, across various therapeutic categories such as oncology, antibiotics, anesthesia, hormones, orthopedics, cardiology, and more. These products are distributed under the company's own brand to hospitals and healthcare centers.

Incorporated as a private limited company on March 10, 2003, Chandra Bhagat Pharma Limited transitioned to a public limited company on March 20, 2019. The company's authorized capital stands at ₹85 million, with a paid-up capital of ₹75.45 million. As of January 10, 2026, the company employs approximately 40 individuals. The registered office is located at 323-F Bhagat Bhuvan, Dr. Ambedkar Road, Matunga (East), Mumbai, Maharashtra, India, 400019.

Chandra Bhagat Pharma Limited operates manufacturing facilities through contract manufacturing arrangements, focusing on the production of pharmaceutical formulations. The company specializes in a range of products, including intravenous and intramuscular injections, tablets, and capsules, catering to both domestic and international markets. By outsourcing manufacturing to third-party contract manufacturers, Chandra Bhagat Pharma Limited ensures compliance with regulatory standards and maintains flexibility in production capacity.

The leadership team at Chandra Bhagat Pharma Limited comprises:

• Hemant Chandravadan Bhagat: Chairman and Managing Director, appointed on March 10, 2003.

• Prachi Pranav Bhagat: Chief Financial Officer and Executive Director, appointed on August 31, 2019.

• Pranav Hemant Bhagat: Whole-Time Director, appointed on May 17, 2004.

• Abha Praveen Doshi: Independent Director, appointed on July 15, 2019.

• Ravindra Gajanan Awati: Independent Director, appointed on July 15, 2019.

Chandra Bhagat Pharma Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary approvals from the U.S. Food and Drug Administration (FDA) for its formulations, enabling manufacturing through contract manufacturers. Additionally, Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals, facilitating access to these regulated markets.

Chandra Bhagat Pharma Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards for its manufacturing facilities enhances its ability to access these markets, as WHO prequalification is often a prerequisite for entry into many emerging economies.

Chandra Bhagat Pharma Limited's geographic strategy demonstrates a balanced approach, with a significant portion of its exports directed towards the "Other" category (48.1%), followed by Advanced Oncology (18.3%) and Respiratory & OTC (14.3%). This diversification indicates a strategic focus on various therapeutic areas and regions, mitigating concentration risk. The company's export portfolio includes nine products across six therapeutic categories, reflecting a broad market presence.

Chandra Bhagat Pharma Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), allowing for the production of pharmaceutical formulations intended for the U.S. market. The company has also obtained necessary approvals for its formulations, enabling manufacturing through contract manufacturers. While specific details regarding approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed, the company's compliance with FDA regulations underscores its commitment to quality and regulatory standards.

Chandra Bhagat Pharma Limited ensures that its products are sourced from qualified factories with a minimum of World Health Organization Good Manufacturing Practice (WHO GMP) approvals. This adherence to WHO GMP standards facilitates access to regulated markets and underscores the company's commitment to quality manufacturing practices.

In India, Chandra Bhagat Pharma Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company also possesses necessary approvals from state drug controllers and export No Objection Certificates (NOCs), enabling the export of its products to various international markets.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Chandra Bhagat Pharma Limited by regulatory authorities. This absence suggests a favorable regulatory standing for the company.

Chandra Bhagat Pharma Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products across overlapping therapeutic categories. While specific market share data is not publicly disclosed, the company's focus on critical care and healthcare products positions it to compete effectively in both domestic and international markets. The company's adherence to WHO GMP standards and its established distribution networks enhance its competitive edge.

Chandra Bhagat Pharma Limited's key differentiators include its long-standing presence in the pharmaceutical industry since 1944, a diverse product portfolio spanning various therapeutic categories, and a commitment to quality manufacturing practices as evidenced by sourcing products from WHO GMP-approved facilities. These factors contribute to the company's competitive advantages in the market.

Chandra Bhagat Pharma Limited's current strategic direction focuses on the marketing of pharmaceutical critical care and healthcare products, with an emphasis on both domestic and international markets. The company's future outlook includes expanding its product portfolio and enhancing its presence in emerging markets, leveraging its adherence to WHO GMP standards and established distribution networks.

Chandra Bhagat Pharma Limited demonstrates a strong track record in the pharmaceutical industry, with a history of introducing several products for the first time in India, such as Anti-Tetanus Serum, Oral Poliomyelitis Vaccine, Anti Diphtheria Sera, Streptokinase, Measles Vaccine, Meningococcal A + C Vaccine, and Human Diploid Rabies Vaccine. The company's export volume and consistency are supported by its adherence to WHO GMP standards and its established distribution networks. Reliability indicators include compliance with regulatory standards and a diverse product portfolio catering to various therapeutic areas.

Importers should verify the following certifications when considering products from Chandra Bhagat Pharma Limited:

• FDA Registration: Confirm the company's manufacturing facilities are registered with the U.S. Food and Drug Administration.

• WHO GMP Certification: Ensure that products are sourced from facilities with World Health Organization Good Manufacturing Practice approvals.

• EU GMP Certification: Verify compliance with European Union Good Manufacturing Practice standards.

• ISO Certification: Check for relevant International Organization for Standardization certifications related to quality management systems.

These certifications can typically be verified through the respective regulatory bodies' official websites or by requesting documentation directly from Chandra Bhagat Pharma Limited.

When conducting due diligence on Chandra Bhagat Pharma Limited, consider the following steps:

• Regulatory Compliance: Verify FDA registration, WHO GMP certification, and other relevant certifications.

• Financial Health: Review the company's financial statements and credit ratings.

• Product Quality: Assess product quality through sampling and third-party testing.

• Supply Chain Reliability: Evaluate the consistency and reliability of the company's supply chain.